ABPI remains concerned over NICE

Healthcare Market News (News) August 2000 The Association of British Pharmaceutical Industries has underlined its concerns over the processes adopted by the National Institute for Clinical Excellence (NICE). The statement coincided with guidance issued by NICE over the use of rosiglitazone for people with type 2 diabetes. Whilst the ABPI welcomed NICE’s endorsement, it questioned…

You must be a HM Subscriber to view this content.

Subscribe Now »